ABSTRACT
An excess of free heme is present in the blood during many types of hemolytic anemia. This has been linked to organ damage caused by heme-mediated oxidative stress and vascular inflammation. We investigated the mechanism of heme-induced coagulation activation in vivo. Heme caused coagulation activation in wild type mice that was attenuated by an anti-tissue factor antibody and in mice expressing low levels of tissue factor. In contrast, neither factor XI deletion nor inhibition of factor XIIa-mediated factor XI activation reduced heme-induced coagulation activation, suggesting that the intrinsic coagulation pathway is not involved. We investigated the source of tissue factor in heme-induced coagulation activation. Heme increased the procoagulant activity of mouse macrophages and human PBMCs. Tissue factor-positive staining was observed on leukocytes isolated from the blood of heme-treated mice but not on endothelial cells in the lungs. Furthermore, heme increased vascular permeability in the mouse lungs, kidney and heart. Deletion of tissue factor from either myeloid cells, hematopoietic and endothelial cells, or inhibition of tissue factor expressed by non-hematopoietic cells did not reduce heme-induced coagulation activation. However, heme-induced activation of coagulation was abolished when both non-hematopoietic and hematopoietic cell tissue factor was inhibited. Finally, we demonstrated that coagulation activation was partially attenuated in sickle cell mice treated with recombinant hemopexin to neutralize free heme. Our results indicate that heme promotes tissue factor-dependent coagulation activation and induces tissue factor expression on leukocytes in vivo. We also demonstrated that free heme may contribute to thrombin generation in a mouse model of sickle cell disease.
INTRODUCTION
Heme is an iron-protoporphyrin complex that plays a central role in oxygen and electron transfer, and is an important functional group in various proteins, for example myoglobin and hemoglobin. As such, heme is critical to oxygen transport, drug metabolism, respiration and signal transduction (1) . Free heme is liberated from hemoglobin released from lysed red blood cells in several pathological states, including bacterial infections, hemolytic anemias and hemoglobinopathies (1) . The plasma proteins haptoglobin and hemopexin scavenge hemoglobin and heme, respectively, and clear them from the blood (2) . Unfortunately, these protective mechanisms can become overwhelmed in many pathological states, resulting in complete depletion of hemopexin and very high levels of free heme in the blood (1, 3) . For example, in sickle cell disease patients, chronic hemolysis results in steady state blood heme levels around 4 μ M, but these levels can reach 20 μ M in some patients (4).
An excess of free heme is highly toxic, because it catalyzes the formation of reactive oxygen species (ROS), leading to oxidative stress and cell injury (1, 5, 6) . Free heme is highly lipophilic and can intercalate in the lipid membranes of the vascular endothelium. These two processes result in endothelial cell (EC) activation, recruiting leukocytes to the endothelium, and initiating an inflammatory response which damages the endothelium and increases vascular permeability (5).
TF is the primary initiator of the extrinsic coagulation cascade, and the TF:FVIIa complex activates both FX and FIX, resulting in thrombin generation, fibrin deposition and platelet activation (7) . TF is constitutively expressed by perivascular cells and is sequestered from the blood, but upon tissue injury it can initiate clotting (8) . Inducible TF expression is also observed on monocytes in various pathological conditions, including sepsis (9, 10) and sickle cell disease (11, 12) . Heme has been demonstrated to induce tissue factor (TF) expression and activity on endothelial cells in vitro (13) . Furthermore, TF expression has been observed on the lung endothelium in mouse models of sickle cell disease (14, 15) . We previously demonstrated that in mouse models of sickle cell disease, TF contributes to both coagulation activation and vascular inflammation (14) .
In this study we investigated the mechanism by which excess of free heme contributes to the activation of coagulation in a mouse model of heme overload.
METHODS

Mice
Male and female C57BL/6 mice (10-12 weeks old) were used for dose response and time course studies. 
Preparation and administration of heme
Porcine heme (Sigma Aldrich, St. Louis, MO) was prepared at 25 mM in 0.1M NaOH and 0.1M Tris-HCl (final pH 8.0), sterile filtered (0.22 µm) and diluted to 10 mM in saline. Vehicle buffer was prepared by diluting sterile-filtered 0.1M NaOH and 0.1M TrisHCl (pH = 8.0) in saline. Mice were anesthetized with isoflurane, and administered heme via RO injection at doses from 0 -35 μ mol/kg (5). These doses are based on the predicted molarity of heme in blood based on the estimated blood volume of the mouse (20) .
Administration of antibodies
C57Bl/6J mice were treated with rat anti-mouse TF (1H1) or control rat IgG antibodies (20 mg/kg) by intraperitoneal injection 30 minutes before heme administration (16) . 1H1 is a monoclonal rat anti-mouse TF antibody that competes for binding of factor VII (21) . Chimeric HTF BM /WT mice were administered anti-human TF (HTF1, 10 mg/kg), antimouse TF (1H1, 20 mg/kg) or control IgG (10 mg/kg) 30 minutes before heme (22) . To inhibit the intrinsic coagulation pathway, C57Bl/6 mice were treated with mouse IgG or the murine monoclonal antibody 14E11 (6 mg/kg) via intraperitoneal (IP) injection 30 minutes before heme administration. This antibody inhibits FXII-dependent activation of FXI and had an anticoagulant effect in a mouse model of sepsis (23, 24) .
Hemopexin treatment of sickle cell mice
We used the Berkley mouse as a model of sickle cell disease (25) . Human hemopexin (Athens Research Technology, Athens, GA) (500 μ g in 100 μ L PBS per 25 gram of body weight; 280 μ mol/kg) was administered to five month old male mice via tail vein injection twice a week for two weeks.
Sample collection and analysis
Mice were anesthetized by isoflurane, and blood was drawn from the inferior vena cava (IVC) into syringes containing 3.8% sodium citrate (final ratio 9:1) and centrifuged at 4,000 x g for 15 minutes at 4ºC. Plasma was collected and immediately stored at -80ºC. Thrombin-antithrombin (TAT) complexes were analyzed using an ELISA kit (Enzygost TAT micro, Siemens Healthcare Diagnostics, Malvern, PA).
Analysis of procoagulant activity, and TF staining
Isolation of human PBMCs and mouse white blood cells, the one-stage clotting assay and TF staining are standard procedures in our laboratory (14, 26) , and are described in detail in the Supplementary Methods.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, San Diego, CA). All data are presented as mean plus or minus SEM. For 2-group comparisons of parametric data, Student t test was performed. For comparisons of more than two groups, one or two way ANOVA with Bonferroni post hoc analysis was performed. Non-normally distributed data was analyzed via Kruskal-Wallis test followed by Wilcoxon-Mann Whitney post hoc analysis. The criterion for significance for all experiments was p<0.05.
RESULTS
Heme causes a dose-and time-dependent activation of coagulation in wild type mice.
Circulating levels of hemopexin in wild type mice are very high (0.5-1.2 g/L) and provide protection against free heme (27) . In contrast, in sickle cell mice, plasma levels of hemopexin are significantly reduced (28) . To study the contribution of free heme to the activation of coagulation, we first determined the minimal amount of heme required to deplete hemopexin levels in wild type mice. We found that neither 3.5 μ mol/kg nor 17.5 μ mol/kg heme affected plasma levels of hemopexin, whereas injection of 35 μ mol/kg of heme resulted in almost completely depletion of hemopexin in the plasma 6 hours after injection ( Figure 1A and B). This observation is consistent with previously reported effects of high doses of heme on plasma levels of hemopexin (6) . Importantly, heme increased plasma levels of TAT in a dose dependent manner with the highest administered dose (35 μ mol/kg) producing a 2.7-fold increase in TAT levels over control ( Figure 1C ). All further experiments were performed with the 35 μ mol/kg dose of heme. In a time course experiment, 35 μ mol/kg heme caused significant coagulation activation as early as 1 hour after administration, which was maintained throughout the course of the experiment ( Figure 1D ).
Heme-mediated coagulation activation is dependent on the extrinsic but not the intrinsic pathway
To determine the role of TF in heme-dependent coagulation activation, we used the rat anti-mouse TF blocking antibody 1H1. Mice were treated with rat IgG or 1H1 (25 mg/kg, IP) 30 minutes prior to heme injection (35 μ mol/kg, RO). Inhibition of TF with 1H1 attenuated coagulation activation in heme treated mice ( Figure 2A ). As an independent approach, we used low TF mice that expressed very low levels of human TF (1% of wild type levels) but not mouse TF (mTF -/-, HTF + ). Similar to anti-TF antibody treated mice, plasma TAT levels were significantly reduced in heme injected low TF mice compared to controls (mTF +/-, HTF + ) ( Figure 2B ).
Next, we investigated if the intrinsic pathway contributes to heme-mediated activation of coagulation. Thirty minutes prior to heme administration, wild type mice were treated with either mouse IgG or the murine monoclonal antibody 14E11 (6 mg/kg, IP), which blocks FXIIa-dependent activation of FXI (24) . Coagulation activation was not attenuated in 14E11-treated mice ( Figure 2C ). Furthermore, FXI-deficient mice were not protected from heme-induced coagulation activation ( Figure 2D ).
Heme induces TF expression on leukocytes
TF expression has been observed in leukocytes isolated from sickle cell patients (11) and sickle cell mice (14) . Therefore, we determined if heme can induce TF expression on leukocytes. RAW 264.7 mouse macrophages were treated with various concentrations of heme (0 -50 μ M) for 6 hours. Heme caused a dose-dependent increase of procoagulant activity (PCA) in RAW 264.7 cells ( Figure 3A) . PCA was also increased in human PBMCs ( Figure 3B ). Furthermore, using immunohistochemistry we analyzed TF protein expression on leukocytes isolated from vehicle or heme-treated mice. We observed TF positive leukocytes isolated from the blood of heme-treated mice but not control mice ( Figure 3C ). In addition, positive TF staining was observed on human PBMCs treated with heme in vitro ( Figure 3D ). Based on the morphology, TF positive staining was observed in both monocytes and neutrophils.
Moreover, we analyzed whether heme induces TF expression in lung endothelial cells. Immunohistochemistry revealed TF positive staining in epithelial and perivascular cells in both control and heme treated mice, but we did not observe TF staining on endothelial cells in any vessels in the lung using this method (Figure 4 ). Perivascular TF can be exposed to circulating clotting factors as a result of vascular damage. To determine if heme damages the vascular endothelium, we measured vascular permeability using the Evans Blue method. In heme-treated mice, we observed an increase in vascular permeability in the heart (1.6 ± 0.2-fold versus control, p=0.041), lung (2.4 ± 0.6-fold versus control, p=0.026), and kidney (1.3 ± 0.2, p=0.05), but not liver, consistent with previous reports (6).
Contribution of different cellular sources of TF to the heme-induced coagulation activation
To determine the cellular source of TF contributing to heme-induced activation of coagulation we first analyzed the effect of TF deletion in myeloid cells. TF flox/flox , LysM Cre+ and control TF flox/flox mice were injected with heme and plasma TAT levels were analyzed 6 hours after injection. We found that deletion of TF from myeloid cells had no effect on heme-dependent activation of coagulation ( Figure 5A ). Plasma TAT levels were also not attenuated in heme-injected TF flox/flox , Tie2 Cre+ mice in which the TF gene is deleted in both hematopoietic cells and endothelial cells ( Figure 5B ).
Since heme-induced vascular permeability may result in the exposure of perivascular TF to circulating factor VII/VIIa, we next investigated the contribution of this source of TF to heme-induced activation of coagulation. We generated chimeric mice that express human TF on hematopoietic cells and murine TF on non-hematopoietic cells (WT recipient mice with bone marrow from HTF mice) and used species-specific antibodies to target the different sources of TF. Mice were treated with either IgG, 1H1 or a combination of 1H1 and HTF-1 (mouse anti-human TF antibody) antibodies. Interestingly, inhibition of non-hematopoietic TF with 1H1 had no effect on hememediated coagulation activation. However, combining 1H1 and HTF-1, to block both non-hematopoietic and hematopoietic sources of TF, respectively, prevented the activation of coagulation by heme in vivo ( Figure 5C ).
Effect of hemopexin treatment on plasma TAT levels in sickle cell mice
In sickle cell disease and other hemolytic anemias, plasma hemopexin levels are depleted by the excess circulating heme. We hypothesized that excess free heme can contribute to the hypercoagulable state observed in sickle cell disease. Therefore, we investigated whether increasing the hemopexin levels in the circulation could attenuate coagulation in a mouse model of sickle cell disease. Consistent with our previous study (25) , plasma TAT levels were significantly elevated in sickle cell mice compared to nonsickle controls ( Figure 6 ). Administration of hemopexin into sickle mice resulted in a 30% decrease of plasma TAT levels, however this change was not statistically different from TAT levels in vehicle-treated sickle mice ( Figure 6 ). This partial reduction in plasma TAT levels suggests that free heme might play a minor role in the hypercoagulable state observed in sickle cell mice.
DISCUSSION
We have demonstrated that an excess of circulating free heme can deplete plasma hemopexin levels and trigger systemic thrombin generation in wild type mice. Furthermore, using both pharmacologic and genetic approaches, we found that hememediated coagulation activation was TF-dependent. It is known that TF expression can be upregulated on leukocytes during many diseases. Therefore, to identify the cellular sources of TF that contribute to heme-mediated activation of coagulation in vivo, we first determined if heme is capable of inducing TF expression on mouse leukocytes. Indeed, heme treatment caused a dose-dependent increase in procoagulant activity in a mouse macrophage cell line, and TF-positive leukocytes were isolated from heme-treated mice.
Despite that, we did not observe an increase in TF-dependent PCA in leukocytes isolated from heme-treated mice (data not shown). The reasons for not seeing the increase in TF-dependent PCA are the very small number of TF-positive monocytes in the heme-treated mice, and the possibility that TF-positive leukocytes become activated, migrate outside the vessels and therefore cannot be isolated from blood. In fact we occasionally observed TF-positive, monocyte-like cells in the lung sections from heme-treated mice (data not shown). Furthermore, heme treatment also increased procoagulant activity and TF expression on human PBMCs. These data indicate that excess free heme can upregulate TF expression on leukocytes. Consistent with these findings, we previously showed that in sickle cell disease, monocyte TF expression is positively correlated with markers of hemolysis and coagulation activation (11) . Surprisingly, deletion of TF from all myeloid cells had no effect on heme-induced coagulation activation in mice, indicating that leukocytes are not the dominant source of TF in these experimental conditions.
Since others have demonstrated that heme induces TF expression and activity on endothelial cells in vitro (13), we first tested whether heme can induce endothelial TF expression in vivo. We focused on the lung vasculature, because it has been reported to be the only vascular bed demonstrating increased TF staining by endothelial cells in mouse models of sickle cell disease (15) . However, we did not observe any TF positive endothelial cells in the lung vasculature of mice treated with heme. Consistent with this result, combined deficiency of TF in both hematopoietic and ECs did not attenuate heme-mediated activation of coagulation. These data suggest that the increased expression of endothelial cell TF observed in sickle cell mice is not solely mediated by free heme. However, we cannot exclude that induction of TF in lung endothelial cells requires prolonged exposure to free heme. Further studies should determine the mechanism of increased TF expression by lung ECs in sickle cell mice.
The fact that deletion of TF from both endothelial and hematopoietic cells did not attenuate heme-dependent coagulation activation led us to hypothesize that heme may damage the vascular endothelium and expose extravascular sources of TF. Indeed, we found increased vascular permeability in the heart, lung and kidneys of heme treated mice. However, inhibition of the non-hematopoietic source of TF alone had no effect on coagulation activation induced by heme. It was only when both non-hematopoietic and hematopoietic cell TF were inhibited that coagulation activation was attenuated. These data suggest that both monocyte and perivascular TF contribute to heme-mediated coagulation activation in vivo. Importantly, the data presented here differ from what we observed in a mouse model of endotoxemia, where LPS-induced coagulation activation was partially attenuated by inhibition of either hematopoietic or non-hematopoietic sources of TF (16) . This difference is most likely explained by the fact that the level of coagulation activation in endotoxemic mice was much greater than in heme-treated mice which allowed us to reveal the partial contribution of TF expressed by both cell types (29) .
It has recently been proposed that in addition to cellular TF, procoagulant microparticles (MPs) may contribute to the propagation of coagulation in various pathologic conditions (30, 31) . MPs are small membrane vesicles released from activated or apoptotic cells. The procoagulant properties of MPs are due to the presence of phosphatidylserine (PS) with or without TF on their surface (30) . Platelet-and erythrocyte-derived MPs, which are TF negative, contribute to thrombin generation in a FXII/FXI-dependent manner, whereas thrombin generation induced by TF-positive leukocyte-derived MPs requires FVII but not FXII (32, 33). In our dose titration and time course experiment, we did not observe any increase in the total number of PS-positive MPs at 1, 3 or 6 hours after heme treatment (data not shown), which may explain the lack of FXI contribution to the heme-induced activation of coagulation. Furthermore, it is unlikely that increased levels of free heme can lead to the activation of FXII because treatment of heme injected mice with 14E11 antibody (an inhibitor of FXIIa-mediated activation of FXI), had no effect on plasma TAT levels. These data strongly support the notion that heme-induced coagulation activation is predominantly driven by TF.
Excess heme has been linked to the pathology of a variety of hemolytic anemias. To examine if the excess of heme can contribute to the activation of coagulation in sickle cell disease, we treated sickle cell mice with recombinant hemopexin. Treatment with hemopexin partially attenuated coagulation activation in sickle cell mice, suggesting that the excess of circulating heme in sickle cell mice might contribute to the hypercoagulable state. Our data contribute to a growing body of evidence suggesting that restoring hemopexin levels in sickle cell mice can be beneficial. Ghosh and colleagues showed that excess heme causes acute chest syndrome in sickle cell mice, and that administration of hemopexin, to reduce plasma levels of free heme, protected sickle mice from acute chest syndrome (28) . Restoring hemopexin also suppressed heme-mediated liver congestion (6), endothelial activation, oxidative stress and cardiovascular dysfunction in sickle cell mice (3). Finally, hemopexin attenuated vascular stasis and vasoocclusion in sickle cell mice (20) . These findings all implicate that administration of hemopexin might have therapeutic potential for sickle cell patients.
Heme has been also suggested to have anti-coagulant properties. Recently it has been shown that heme can bind FVIII in vitro and inhibit its procoagulant properties (34) . However, heme could only inhibit the procoagulant functions of FVIII when administered in a molar excess and in the absence of von Willebrand Factor (VWF) which is a natural chaperone of FVIII (34) . This suggests that an excess of heme might have an anti-coagulant effect, but this remains to be tested in vivo. However, Belcher and colleagues recently demonstrated that heme rapidly triggers the release of VWF from EC both in vitro and in vivo (20) which would diminish the anticoagulant properties of heme and support the procoagulant role that we observed.
In summary, our data indicate that an excess of heme promotes systemic thrombin generation in mice that is dependent on the extrinsic coagulation pathway but not the intrinsic pathway. Furthermore, we demonstrate that excess heme can increase TF expression and procoagulant activity on leukocytes both in vitro and in vivo, and that heme increases vascular permeability and exposes extravascular TF. Using cell-type specific knockouts and chimeric mice, we showed that mice are protected from hemeinduced coagulation activation only when all cellular sources of TF are inhibited. Finally, we demonstrated that hemopexin partially attenuated thrombin generation in sickle cell mice, suggesting that excess heme influences coagulation, and might contribute, in part, to the thrombotic complications of sickle cell disease. 
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